INTERPRET: Understanding Immunotherapy Response in Cancer
This study, called INTERPRET, is looking at how your body responds to immunotherapy treatments for cancer. Researchers want to understand why some people respond well to immunotherapy and others don't, and why some people experience side effects. They will do this by collecting blood samples at different times while you are receiving immunotherapy. They will measure certain substances in your blood and look at your immune cells to see if there are patterns that predict how well the treatment works or if side effects develop. You can join if you are at least 18 years old, have a cancer diagnosis, and are starting immunotherapy. The study aims to enroll 100 participants, but its current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will collect information without giving you a specific treatment. It plans to include 100 participants.
- What's involved
- You would provide blood samples at 1 to 10 different times, starting around when you begin immunotherapy and continuing for up to 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your blood will be analyzed for up to 12 months after you start immunotherapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tyler Shugg, PharmD, PhD · PRINCIPAL_INVESTIGATOR · Indiana University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Quantification of plasma concentrationsthrough study completion (i.e. up to 12 months)
Including cytokines, chemokines, growth factors, and other relevant immunologic molecules from blood samples
- Profiling of immune cellsthrough study completion (i.e. up to 12 months)
Plasma concentrations of immunologic molecules will be assayed using immunoassays or plasma proteomic approaches. Profiling of immune cells will be performed using flow cytometry, RNA sequencing, and other established approaches.